Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant610 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02178722 | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | completed | Phase 1 / Phase 2 | 444 | Incyte CorporationINDUSTRY | 1 | Feb 14, 2022 | clinicaltrials |
| NCT03696069 | A Study is to Understand the Treatment Patterns for Immunotherapy Agents and BRAF/MEK Inhibitors Used in the Treatment of Advanced Melanoma | completed | — | 501 | Bristol-Myers SquibbINDUSTRY | 1 | Feb 10, 2022 |
| clinicaltrials |
| NCT01391143 | Safety Study of MGA271 in Refractory Cancer | completed | Phase 1 | 179 | MacroGenicsINDUSTRY | 1 | Feb 8, 2022 | clinicaltrials |
| NCT01827111 | Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma | completed | Phase 2 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 8, 2022 | clinicaltrials |
| NCT02381314 | Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer | completed | Phase 1 | 24 | MacroGenicsINDUSTRY | 1 | Feb 8, 2022 | clinicaltrials |
| NCT02482532 | Vaccine Enriched, Autologous, Activated T-Cells Directed to Tumor in Patients With Relapsed/Refractory Melanoma(MARVSmALo) | completed | Phase 1 | 7 | Gary DoolittleOTHER | 1 | Feb 4, 2022 | clinicaltrials |
| NCT03278665 | 4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy(SENSITIZE) | completed | Phase 1 / Phase 2 | 40 | 4SC AGINDUSTRY | 2 | Feb 4, 2022 | clinicaltrials |
| NCT02083354 | Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma | completed | Phase 2 | 77 | Novartis PharmaceuticalsINDUSTRY | 5 | Feb 1, 2022 | clinicaltrials |
| NCT02402699 | Ipilimumab 60-month Pharmacovigilance Protocol for Advanced Melanoma Patients Who Are Hepatitis B and/or Hepatitis C Virus Positive in Taiwan(Yervoy RMP) | completed | — | 3 | Bristol-Myers SquibbINDUSTRY | 1 | Jan 26, 2022 | clinicaltrials |
| NCT03745872 | SunSmart Intervention in Schools | completed | N/A | 76 | University of Colorado, DenverOTHER | 1 | Jan 4, 2022 | clinicaltrials |
| NCT01511913 | A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma(IMAGE) | completed | — | 1,411 | Bristol-Myers SquibbINDUSTRY | 15 | Dec 28, 2021 | clinicaltrials |
| NCT04217382 | Pre Transplantation Melanoma(MPG) | completed | — | 37 | Hospices Civils de LyonOTHER | 1 | Dec 10, 2021 | clinicaltrials |
| NCT02225366 | Intratumoral Injections of LL37 for Melanoma | completed | Phase 1 / Phase 2 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 9, 2021 | clinicaltrials |
| NCT00910650 | Study of Gene Modified Immune Cells in Patients With Advanced Melanoma(F5) | completed | Phase 2 | 14 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Dec 6, 2021 | clinicaltrials |
| NCT00730639 | A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies(MDX1106-03) | completed | Phase 1 | 395 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 3, 2021 | clinicaltrials |
| NCT02366195 | Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma(TVEC-325) | completed | Phase 2 | 112 | AmgenINDUSTRY | 13 | Nov 30, 2021 | clinicaltrials |
| NCT02716948 | SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine | completed | Phase 1 | 17 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 30, 2021 | clinicaltrials |
| NCT00591734 | RAD001 Plus Bevacizumab in Metastatic Melanoma | completed | Phase 2 | 57 | SCRI Development Innovations, LLCOTHER | 1 | Nov 24, 2021 | clinicaltrials |
| NCT04420273 | Targeted Melanoma Detection With Skin Self-Examination During COVID-19 Restricted Physician Access(TMD) | completed | N/A | 1,000 | Northwestern UniversityOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT02009397 | A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients | completed | Phase 1 / Phase 2 | 27 | University of LouisvilleOTHER | 1 | Nov 22, 2021 | clinicaltrials |
| NCT03319459 | FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors | completed | Phase 1 | 44 | Fate TherapeuticsINDUSTRY | 1 | Nov 22, 2021 | clinicaltrials |
| NCT02129075 | A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Nov 16, 2021 | clinicaltrials |
| NCT03652077 | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | completed | Phase 1 | 40 | Incyte CorporationINDUSTRY | 1 | Nov 15, 2021 | clinicaltrials |
| NCT03508297 | Reflectance Confocal Microscopy to Diagnose MM & LM | completed | — | 597 | Skin Care Network Ltd.INDUSTRY | 1 | Nov 12, 2021 | clinicaltrials |
| NCT02983006 | Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma | completed | Phase 1 | 12 | NYU Langone HealthOTHER | 1 | Oct 18, 2021 | clinicaltrials |
| NCT03409419 | PET Imaging of the Immune System Using Analog Probes | completed | — | 4 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Oct 12, 2021 | clinicaltrials |
| NCT02320058 | An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself(CheckMate204) | completed | Phase 2 | 119 | Bristol-Myers SquibbINDUSTRY | 1 | Oct 5, 2021 | clinicaltrials |
| NCT02173171 | Registry Study for Talimogene Laherparepvec | completed | — | 185 | AmgenINDUSTRY | 15 | Sep 30, 2021 | clinicaltrials |
| NCT05063058 | Biomarker-driven Therapy for Melanoma(TREAT20plus) | completed | N/A | 100 | Charite University, Berlin, GermanyOTHER | 0 | Sep 30, 2021 | clinicaltrials |
| NCT03663647 | Advanced Melanoma in Russian Experience(ADMIRE) | completed | — | 382 | MelanomaPRO, RussiaOTHER | 1 | Sep 29, 2021 | clinicaltrials |
| NCT02574377 | myDC/pDC in Stage III Melanoma Patients | completed | Phase 1 / Phase 2 | 30 | Radboud University Medical CenterOTHER | 1 | Sep 20, 2021 | clinicaltrials |
| NCT03068455 | An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma(CheckMate 915) | completed | Phase 3 | 1,844 | Bristol-Myers SquibbINDUSTRY | 19 | Sep 20, 2021 | clinicaltrials |
| NCT03325257 | Post-ATU Study of Nivolumab(Post-ATU) | completed | — | 350 | Nantes University HospitalOTHER | 1 | Sep 14, 2021 | clinicaltrials |
| NCT01335009 | Efficacy Study of Pharmacokinetic(PK)/Pharmacodynamic(PD) Relationship of Monotherapy MORAb-004 in Metastatic Melanoma | completed | Phase 2 | 76 | Eisai Inc.INDUSTRY | 4 | Sep 1, 2021 | clinicaltrials |
| NCT04040114 | Improving Skin Cancer Management With Artificial Intelligence (04.17 SMARTI)(SMARTI) | completed | N/A | 200 | Melanoma and Skin Cancer Trials LimitedOTHER | 1 | Aug 19, 2021 | clinicaltrials |
| NCT00960752 | Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist | completed | Phase 2 | 47 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 13, 2021 | clinicaltrials |
| NCT01783938 | Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064) | completed | Phase 2 | 138 | Bristol-Myers SquibbINDUSTRY | 1 | Aug 13, 2021 | clinicaltrials |
| NCT04123678 | DERM Health Economics Study | completed | — | 700 | Skin Analytics LimitedINDUSTRY | 1 | Aug 13, 2021 | clinicaltrials |
| NCT02071940 | PLX3397 KIT in Acral aNd mucOsal Melanoma(PIANO) | completed | Phase 2 | 7 | The Christie NHS Foundation TrustOTHER | 1 | Aug 12, 2021 | clinicaltrials |
| NCT02807844 | Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 141 | Novartis PharmaceuticalsINDUSTRY | 11 | Aug 11, 2021 | clinicaltrials |
| NCT01497808 | RADVAX™: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMA | completed | Phase 1 / Phase 2 | 22 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Aug 10, 2021 | clinicaltrials |
| NCT03979872 | Risk Information and Skin-cancer Education for Undergraduate Prevention(RISE-UP) | completed | N/A | 92 | University of UtahOTHER | 1 | Jul 13, 2021 | clinicaltrials |
| NCT03329846 | An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma | completed | Phase 3 | 20 | Bristol-Myers SquibbINDUSTRY | 16 | Jul 9, 2021 | clinicaltrials |
| NCT00324727 | Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma | completed | Phase 3 | 93 | Delcath Systems Inc.INDUSTRY | 1 | Jun 21, 2021 | clinicaltrials |
| NCT02599402 | Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma(CheckMate 401) | completed | Phase 3 | 533 | Bristol-Myers SquibbINDUSTRY | 12 | Jun 15, 2021 | clinicaltrials |
| NCT00414765 | Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma | completed | Phase 4 | 26 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 8, 2021 | clinicaltrials |
| NCT02296112 | Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations | completed | Phase 2 | 9 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | May 28, 2021 | clinicaltrials |
| NCT02112032 | Treatment of Advanced Melanoma With MK-3475 and Peginterferon | completed | Phase 1 | 43 | Hassane M. Zarour, MDOTHER | 1 | May 5, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Feb 14, 2022source: clinicaltrials